• Publications
  • Influence
Glioblastoma and other malignant gliomas: a clinical review.
TLDR
The clinical management of malignant gliomas is reviewed, including genetic and environmental risk factors such as cell phones, diagnostic pitfalls, symptom management, specific antitumor therapy, and common complications.
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
TLDR
Analysis of advanced cancer patients treated with immune-checkpoint inhibitors shows that tumor mutational burden, as assessed by targeted next-generation sequencing, predicts survival after immunotherapy across multiple cancer types.
Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model.
TLDR
The MSKCC prognostic score is a simple, statistically powerful model with universal applicability to patients with newly diagnosed PCNSL and is recommended that it be adopted for the management of newly diagnosed patients and incorporated into the design of prospective clinical trials.
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
TLDR
This is the first multicenter trial demonstrating improved survival with the combination of chemotherapy plus RT compared with previous reports of RT alone, and high-dose methotrexate combined with cranial irradiation is an effective therapeutic approach to PCNSL, but neurotoxicity is a delayed risk of this approach.
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.
TLDR
The findings implicate cellular components other than T cells and suggest novel links between systemic inflammation and characteristic neurotoxicity symptoms and identify neurotoxicity risk factors.
Long-term survival in primary CNS lymphoma.
TLDR
Combined modality therapy for PCNSL has improved survival, but relapse is common and late neurologic toxicity is a significant complication, and efficacious but less neurotoxic regimens need to be developed for older patients.
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
TLDR
An international group of experts meeting to review current standards of reporting and to formulate a consensus opinion regarding minimum baseline evaluation and common standards for assessing response to therapy hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow to develop better therapies for patients.
Treatment for primary CNS lymphoma: the next step.
TLDR
Increasing the dose of MTX and adding procarbazine and vincristine improved disease control and overall survival in patients with newly diagnosed PCNSL and younger patients in particular fared extremely well with this treatment regimen.
Combined modality therapy for primary CNS lymphoma.
TLDR
The addition of chemotherapy to cranial RT for initial treatment ofPCNSL significantly improved disease-free survival and contributed to overall survival; all non-AIDS patients with newly diagnosed PCNSL should be considered for combined modality therapy.
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
TLDR
The addition of rituximab to MPV increased the risk of significant neutropenia requiring routine growth factor support, and reduced-dose whole-brain radiotherapy (WBRT) after CR was not associated with neurocognitive decline, and disease control to date is excellent.
...
1
2
3
4
5
...